Ketoconazole
- Generic Name
- Ketoconazole
- Brand Names
- Extina, Ketodan, Ketoderm, Nizoral, Xolegel, Ketoconazole HRA
- Drug Type
- Small Molecule
- Chemical Formula
- C26H28Cl2N4O4
- CAS Number
- 65277-42-1
- Unique Ingredient Identifier
- R9400W927I
- Background
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections. It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus. Ketoconazole was first approved in an oral formulation for systemic use by...
- Indication
Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. In Europe, it is also used in the treatment of endogenous Cushing's syndrome.
- Associated Conditions
- Bacterial Vaginosis (BV), Blastomycosis, Candidiasis, Systemic, Chromoblastomycosis, Chronic Mucocutaneous Candidiasis (CMC), Coccidioidomycosis, Dandruff, Endogenous Cushing's Syndrome, Fungal Infections, Histoplasmosis, Paracoccidioidomycosis, Seborrheic Dermatitis, Tinea Corporis caused by Epidermophyton floccosumin, Tinea Corporis caused by Trichophyton mentagrophytes, Tinea Corporis caused by Trichophyton rubrum, Tinea Cruris caused by Epidermophyton floccosumin, Tinea Cruris caused by Trichophyton mentagrophytes, Tinea Cruris caused by Trichophyton rubrum, Tinea Pedis caused by Epidermophyton floccosumin, Tinea Pedis caused by Trichophyton mentagrophytes, Tinea Pedis caused by Trichophyton rubrum, Vaginal Candidiasis, Vulvovaginal Candidiasis, Cutaneous candidiasis, Recalcitrant Dermatophytosis, Tinea versicolor caused by Malassezia infection
- Associated Therapies
- -
A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers
- Conditions
- Interventions
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01476800
- Locations
- 🇺🇸
MDS Pharma Services (US) Inc., Lincoln, Nebraska, United States
Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01473316
Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Allergan
- Target Recruit Count
- 24
- Registration Number
- NCT01468558
- Locations
- 🇬🇧
Simbec Research Limited, Merthyr Tydfil, United Kingdom
Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT01454076
A Study of LY2484595 on Pharmacokinetics in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 82
- Registration Number
- NCT01448824
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
Pharmacokinetic Drug Interaction Study in Healthy Male Subjects
- First Posted Date
- 2011-09-01
- Last Posted Date
- 2011-09-01
- Lead Sponsor
- LG Life Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT01426906
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban)
- Conditions
- Interventions
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2014-03-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 26
- Registration Number
- NCT01405989
- Locations
- 🇫🇷
SGS Aster, Paris, France
Effect of Ketoconazole on Breathlessness
- Conditions
- Interventions
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01378520
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2011-04-25
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT01340846
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 15
- Registration Number
- NCT01324310
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇬🇧Sarah Cannon Research UK, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.